期刊
JOURNAL OF MEDICINAL CHEMISTRY
卷 59, 期 15, 页码 7188-7211出版社
AMER CHEMICAL SOC
DOI: 10.1021/acs.jmedchem.6b00709
关键词
-
资金
- University of Bern
- Swiss National Science Foundation program NCCR Chemical Biology
- Swiss National Science Foundation program NCCR TransCure
- Marie Heim-Vogtlin grant
Here we report the discovery of a selective inhibitor of Aurora A, a key regulator of cell division and potential anticancer target. We used the atom category extended ligand overlap score (xLOS), a 3D ligand-based virtual screening method recently developed in our group, to select 437 shape and pharmacophore analogs of reference kinase inhibitors. Biochemical screening uncovered two inhibitor series with scaffolds unprecedented among kinase inhibitors. One of them was successfully optimized by structure-based design to a potent Aurora A inhibitor (IC50 = 2 nM) with very high kinome selectivity for Aurora kinases. This inhibitor locks Aurora A in an inactive conformation and disrupts binding to its activator protein TPX2, which impairs Aurora A localization at the mitotic spindle and induces cell division defects. This phenotype can be rescued by inhibitor resistant Aurora A mutants. The inhibitor furthermore does not induce Aurora B specific effects in cells.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据